Copyright (c) 2023 GIRISH K. DESHPANDE, PARAMESWARI AKSHINTHALA, NARESH KUMAR KATARI, BALASAHEB DESHMUKH, LEELA PRASAD KOWTHARAPU, SREENIVAS RAO BATTULA, RAMBABU GUNDLA
This work is licensed under a Creative Commons Attribution 4.0 International License.
Evaluation of Physico-Chemical Properties Influence on Drug Product in vitro Profiles and Solubility Profile of Fourth Generation Antibacterial Drug
Corresponding Author(s) : SREENIVAS RAO BATTULA
Asian Journal of Chemistry,
Vol. 35 No. 10 (2023): Vol 35 Issue 10, 2023
Abstract
Moxifloxacin hydrochloride drug substance used to treat bacterial infections in many different parts of the body and most widely used worldwide. In this study, various high-end physico-chemical techniques are used like PXRD, DSC, TGA, BET SSA and PSD analysis to check the relative differences on the product behaviour. The present work reports an impact of alteration in particle size due to compaction process where increase in particle size has been observed from 15.912 μm to 751.001 μm, decrease in specific surface area from 1.89 m2/g to 0.861 m2/g, decrease in crystallinity from 91.65% to 59.15% and impact of dehydration or loss of water from 3.776% to 1.866%, which were observed during study. All the alterations in the physico-chemical properties impacting the drug manufacturing process and on the bioperformance of the finished product. This research attempt aims to investigate the effects of these modifications on in vitro experiments conducted in the office of generic drugs (OGD) media and the equilibrium solubility profile. The in vitro studies resulted about 35% release difference observed in the initial time points, whereas solubility in water observed about 17 mg/mL difference. This research work helps to demonstrate the optimization of finished product development process to meet the biofriendly formulation.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- D.C. Hooper and G.A. Jacoby, Cold Spring Harb Perspect Med., 6, a025320 (2016); https://doi.org/10.1101/cshperspect.a025320
- R.E. Ashley, A. Dittmore, S.A. McPherson, C.L. Turnbough Jr., K.C. Neuman and N. Osheroff, Nucleic Acids Res., 45, 9611 (2017); https://doi.org/10.1093/nar/gkx649
- S.J. McKie, K.C. Neuman and A. Maxwell, BioEssays, 43, 2000286 (2021); https://doi.org/10.1002/bies.202000286
- E.L. Zechiedrich and N.R. Cozzarelli, Genes Dev., 9, 2859 (1995); https://doi.org/10.1101/gad.9.22.2859
- K.D. Corbett, R.K. Shultzaberger and J.M. Berger, PNAS, 101, 7293 (2004); https://doi.org/10.1073/pnas.0401595101
- F. Tian, H. Qu, A. Zimmermann, T. Munk, A.C. Jørgensen and J. Rantanen, J. Pharm. Pharmacol., 62, 1534 (2010); https://doi.org/10.1111/j.2042-7158.2010.01186.x
- C. Lester, G. Lubey, M. Dicks, G. Andol, D. Vaughn, R.T. Cambron, K. Poiesz and N. RedmanFurey, J. Pharm. Sci., 95, 2631 (2006); https://doi.org/10.1002/jps.20662
- S.L. Price and S.M. Reutzel-Edens, Drug Discov. Today, 21, 912 (2016); https://doi.org/10.1016/j.drudis.2016.01.014
- D.M. Raut, R. Allada, K.V. Pavan, G. Deshpande, D. Patil, A. Patil, A. Deshmukh, D.M. Sakharkar, P.S. Bodke and D.T. Mahajan, Der Pharm. Lett., 3, 202 (2011).
- D.E. Braun, L.H. Koztecki, J.A. McMahon, S.L. Price and S.M. Reutzel-Edens, Mol. Pharmaceutics, 12, 3069 (2015); https://doi.org/10.1021/acs.molpharmaceut.5b00357
- L. Borka, Pharm. Acta Helv., 66, 16 (1991).
- J.H. Kirk, S.E. Dann and C.G. Blatchford, Int. J. Pharm., 334, 103 (2007); https://doi.org/10.1016/j.ijpharm.2006.10.026
- N.L. Redman-Furey, W.J. Collins and M.A. Burgin, Thermoanalytical Characterization of the Hydration States of Risedronate. In Proceedings of the 30th North American Thermal Analysis Society Conference, pp. 733-738 (2002).
- D. Giron, Thermochim. Acta, 248, 1 (1995); https://doi.org/10.1016/0040-6031(94)01953-E
- N. Redman-Furey, M. Dicks, A. Bigalow-Kern, R.T. Cambron, G. Lubey, C. Lester and D. Vaughn, J. Pharm. Sci., 94, 893 (2005); https://doi.org/10.1002/jps.20308
References
D.C. Hooper and G.A. Jacoby, Cold Spring Harb Perspect Med., 6, a025320 (2016); https://doi.org/10.1101/cshperspect.a025320
R.E. Ashley, A. Dittmore, S.A. McPherson, C.L. Turnbough Jr., K.C. Neuman and N. Osheroff, Nucleic Acids Res., 45, 9611 (2017); https://doi.org/10.1093/nar/gkx649
S.J. McKie, K.C. Neuman and A. Maxwell, BioEssays, 43, 2000286 (2021); https://doi.org/10.1002/bies.202000286
E.L. Zechiedrich and N.R. Cozzarelli, Genes Dev., 9, 2859 (1995); https://doi.org/10.1101/gad.9.22.2859
K.D. Corbett, R.K. Shultzaberger and J.M. Berger, PNAS, 101, 7293 (2004); https://doi.org/10.1073/pnas.0401595101
F. Tian, H. Qu, A. Zimmermann, T. Munk, A.C. Jørgensen and J. Rantanen, J. Pharm. Pharmacol., 62, 1534 (2010); https://doi.org/10.1111/j.2042-7158.2010.01186.x
C. Lester, G. Lubey, M. Dicks, G. Andol, D. Vaughn, R.T. Cambron, K. Poiesz and N. RedmanFurey, J. Pharm. Sci., 95, 2631 (2006); https://doi.org/10.1002/jps.20662
S.L. Price and S.M. Reutzel-Edens, Drug Discov. Today, 21, 912 (2016); https://doi.org/10.1016/j.drudis.2016.01.014
D.M. Raut, R. Allada, K.V. Pavan, G. Deshpande, D. Patil, A. Patil, A. Deshmukh, D.M. Sakharkar, P.S. Bodke and D.T. Mahajan, Der Pharm. Lett., 3, 202 (2011).
D.E. Braun, L.H. Koztecki, J.A. McMahon, S.L. Price and S.M. Reutzel-Edens, Mol. Pharmaceutics, 12, 3069 (2015); https://doi.org/10.1021/acs.molpharmaceut.5b00357
L. Borka, Pharm. Acta Helv., 66, 16 (1991).
J.H. Kirk, S.E. Dann and C.G. Blatchford, Int. J. Pharm., 334, 103 (2007); https://doi.org/10.1016/j.ijpharm.2006.10.026
N.L. Redman-Furey, W.J. Collins and M.A. Burgin, Thermoanalytical Characterization of the Hydration States of Risedronate. In Proceedings of the 30th North American Thermal Analysis Society Conference, pp. 733-738 (2002).
D. Giron, Thermochim. Acta, 248, 1 (1995); https://doi.org/10.1016/0040-6031(94)01953-E
N. Redman-Furey, M. Dicks, A. Bigalow-Kern, R.T. Cambron, G. Lubey, C. Lester and D. Vaughn, J. Pharm. Sci., 94, 893 (2005); https://doi.org/10.1002/jps.20308